| Prev Close | 18.42 |
| Day Low/High | 17.70 / 18.65 |
| 52 Wk Low/High | 15.02 / 25.31 |
| Avg Volume | 3.28M |
Exelixis Inc. (EXEL)
18.59
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 303.85M |
| Market Cap | 5.60B |
| EPS | 1.10 |
| P/E Ratio | 18.06 |
| Div & Yield | N.A. (N.A) |
Latest News
2 Potential Targets as Biotech Acquisition Activity Heats Up
TG Therapeutics and Exelixis could find themselves on the shopping lists of other companies.
2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land
These two firms have successful drugs and could make nice additions for larger companies.
A Six-Pack of Biotech Best Bets
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
News Surrounds 3 Small Biotechs, With a Merger Claiming One
Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.
How I Use Options to Mitigate Risk and Create Income
Buy-write strategies give you confidence to 'buy the dip' while also adding an extra income stream.
Rules of Biotech Investing Change, and So Must Biotech Investors
One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.
Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
These 'Small Ball' Names Will Outperform the Market in 2019
Investors are already more focused on what lies ahead when Q1 results start in early April.
My 2 Top Stock Picks for 2019
It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.
Celgene Deal Gets the M&A Ball Rolling in the New Year
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
3 Profitable Small Biotech Names to Consider
Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.
Here's a Handful of Ways to Navigate Biotech's Choppy Seas
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
Here's How I'm Playing Biotech Now
I continue to deploy 'dry powder' into the biotech sector on dips using Buy-Write option strategies.
Small Biotechs Finally Join in Market Rebound
Exelixis Inc. and Aratana Therapeutics in particular surge after posting solid results Thursday.
3 Small Biotech Stocks to Watch in the Fourth Quarter
These are just a few of the names I expect to do well to close out 2018.
3 Small Biotechs on My Q4 Watch List
These are a few of the names I expect to do well to close out 2018.
Synchrony, Exelixis Look Like Good Values
The credit card provider and the biotech concern appear cheap relative to their potential.
Two Oncology Stocks I Like Now
M&A activity should pick up in the biotech space.
Which Hot Biotech Name Will Be Acquired Next?
Your burning biotech questions answered in our latest mailbag.
Bret Jensen's Biotech Mailbag
We'll answer two of the common questions we have received so far in March.
Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers
The South San Francisco, Calif.-based company said Oct. 16 its Phase 3 study of cabozantinib achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma.
Exelixis Has an Enviable Chart Pattern
The $30 area is probably up next.
Fewer Oars Make Market Tough Row to Hoe
Investors should be more cautious heading into the summer.
These Stocks Are Changing Direction
Finding bullish and bearish reversals in the market.
Biotech Heating up on M&A Speculation
The market is pretty close to where it was during our last update at noon EST. So far it has been a nicely green day across the board. Oncology mid-cap concern Tesaro is not giving up its big takeover speculation rise yesterday and is up another 3%...
Hopes for Tax Reform, Less Regulation Lift Indices
Technical indicators indicate the markets are not extended and have consolidated nicely.
The Next Target in Biotech Land
The Actelion buyout opens the way for other deals.
